Stryker MedSurg and Neurotechnology — Capital Expenditures During Period increased by 23.4% to $58.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 9.4%, from $53.00M to $58.00M. Over 3 years (FY 2021 to FY 2024), MedSurg and Neurotechnology — Capital Expenditures During Period shows an upward trend with a 11.9% CAGR.
Higher capital expenditures indicate investment in future growth and capacity, while lower levels may suggest a focus on cash preservation or a mature asset base.
Measures the cash spent by the MedSurg and Neurotechnology segment to acquire, upgrade, or maintain physical assets such...
Standard metric for assessing capital intensity and growth investment across the medical device sector.
syk_segment_medsurg_and_neurotechnology_capital_expenditures_during_period| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $49.25M | $49.25M | $49.25M | $43.25M | $43.25M | $43.25M | $43.25M | $44.75M | $44.75M | $44.75M | $44.75M | $41.00M | $42.00M | $53.00M | $140.00M | $48.00M | $47.00M | $58.00M |
| QoQ Change | — | +0.0% | +0.0% | -12.2% | +0.0% | +0.0% | +0.0% | +3.5% | +0.0% | +0.0% | +0.0% | -8.4% | +2.4% | +26.2% | +164.2% | -65.7% | -2.1% | +23.4% |
| YoY Change | — | — | — | — | -12.2% | -12.2% | -12.2% | +3.5% | +3.5% | +3.5% | +3.5% | -8.4% | -6.1% | +18.4% | +212.8% | +17.1% | +11.9% | +9.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.